Skip to main content

Table 3 Factors associated with Treatment failure of 262 patients with M/XDR-TB

From: Treatment outcomes of patients with multidrug and extensively drug-resistant tuberculosis in Zhejiang, China

Chracteristic Treatment successc Treatment failure Total Univariate analysis Multivariate analysis
Cure, TC n(%) Failure (n,%) N (%) OR (95% CI)d P OR (95% CI) P
Sex
 Male 105 54.69 42 21.88 192 73.28 1.25(0.656–2.383) 0.498 0.66(0.109–4.011) 0.652
 Female 40 57.14 20 28.57 70 26.72 1   1  
Age           
  < 60 year 124 62.94 35 17.77 197 75.19 4.555(2.302–9.015) 0.000 9.053(1.606–51.027) 0.013
  ≥ 60 year 21 32.31 27 41.54 65 24.81 1   1  
Occupationa           
 Farmer 108 54.82 47 23.86 197 75.19 0.932(0.467–1.859) 0.841 1.343(0.262–6.898) 0.724
 Others 37 56.92 15 23.08 65 24.81 1   1  
Family registerb           
 Resident 62 50 38 30.65 124 47.33 0.472(0.257–0.866) 0.015 5.502(0.778–38.935) 0.088
 Floating 83 60.14 24 17.39 138 52.67 1   1  
Previous TB treatment           
 No 14 66.67 4 19.05 21 8.02 1.55(0.489–4.911) 0.457 2.033(0.113–36.662) 0.631
 Yes 131 54.36 58 24.07 241 91.98 1   1  
Weight           
  < 50 kg 19 44.19 16 37.21 43 16.41 2.824(1.198–6.657) 0.018 8.668(1.679–44.756) 0.01
  >  = 50 kg 57 64.04 17 19.1 89 33.97 1   1  
TB symptoms           
Hemoptysis         
 Yes 105 58.01 38 20.99 181 69.08 0.603(0.322–1.129) 0.114 8.928(1.048–76.923) 0.045
 No 40 49.38 24 29.63 81 30.92 1   1  
Cavitary           
 Yes 42 33.07 42 33.07 127 48.47 5.154(2.71–9.803) 0.000 10.204(2.032–52.631) 0.005
 No 103 76.3 20 14.81 135 51.53 1   1  
Treatment           
 Standard treatment 136 57.87 53 22.55 235 89.69 2.566(0.966–6.816) 0.059 0.447(0.027–7.449) 0.575
 Individualized treatment 9 33.33 9 33.33 27 10.31 1   1  
Hosipitalization          
 No 115 58.67 41 20.92 196 74.81 0.509(0.263–0.987) 0.046 0.365(0.066–2.009) 0.247
 Yes 30 45.45 21 31.82 66 25.19 1   1  
Liver protection drugs          
 Yes 38 48.72 24 30.77 78 29.77 1.779(0.946–3.344) 0.074 1.764(0.935–142.857) 0.056
 NO 107 58.15 38 20.65 184 70.23 1   1  
First-line oral anti-TB agents          
Ethambutol           
 R 58 54.21 25 23.36 107 40.84 0.987(0.538–1.81) 0.965 1.721(0.37–8.009) 0.489
 S 87 56.13 37 23.87 155 59.16 1   1  
Injectable anti-TB agents          
Streptomycin           
 R 92 57.5 34 21.25 160 61.07 1.43(0.782–2.614) 0.246 1.85(0.46–7.451) 0.387
 S 53 51.96 28 27.45 102 38.93 1   1  
Kanamycin           
 R 7 36.84 9 47.37 19 7.25 0.299(0.106–0.843) 0.022 0.137(0.005–3.663) 0.236
 S 138 56.79 53 21.81 243 92.75 1   1  
Fluoroquinolones          
Ofloxacin           
 R 14 35.9 14 35.9 39 14.89 0.366(0.163–0.825) 0.015 0.793(0.101–6.209) 0.825
 S 131 58.74 48 21.52 223 85.11 1   1  
Treatment regularity          
 No 2 7.14 18 64.29 28 10.69 29.411(6.535–125) 0.000 47.619(5.025–500) 0.001
 Yes 143 61.11 44 18.8 234 89.31 1   1  
Resistant patterne          
 R/H 38 52.05 21 28.77 73 27.86 0.693(0.364–1.319)    
 R/H/E 13 61.90 4 19.05 21 8.02 1.428(0.447–4.566)    
 R/H/S 42 66.67 11 17.46 63 24.05 1.891(0.899–3.978)    
 R/H/S/E 37 56.92 12 18.46 65 24.81 1.427(0.686–2.969)    
 R/H/Ofx/Km/S/E 3 30.00 6 60.00 10 3.82 0.131(0.026–0.666) 0.014   
  1. aothers including student and other occupation not investigated in specific
  2. bpermanent local residence classified into “residence”, otherwise “Floating”
  3. cTreatment success including cured(Cure)and treatment completed(TC)
  4. dOR adjusted odd ratio, CI confidence interval
  5. eH isoniazid, R rifampicin, E ethambutol, S streptomycin, Km kanamycin, Ofx ofloxacin. Analysis was done for patterns with at least 10 cases in total